BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 3, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» Invivyd selects VYD-222 to advance as monoclonal antibody therapeutic option for COVID-19
To read the full article
sign up for free
or
sign in
.
Infection
Invivyd selects VYD-222 to advance as monoclonal antibody therapeutic option for COVID-19
March 7, 2023
Invivyd Inc. has selected VYD-222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19. VYD-222...
BioWorld Science
Immune
Infection
Coronavirus
Monoclonal antibody